Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CO-2
- Development stage
- Preclinical
- Lead developer
- Congruence Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CO-2 is an orally active small molecule pharmacological corrector being developed by Congruence Therapeutics for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). Discovered using the proprietary Revenir™ computational platform, the drug targets the SERPINA1 gene product, alpha-1 antitrypsin (A1AT). Its mechanism of action involves stabilizing the protein to increase the secretion of functional AAT into the bloodstream while simultaneously reducing the toxic accumulation of polymerized mutant protein within hepatocytes. This dual approach aims to mitigate both the lung disease (emphysema) caused by AAT deficiency and the liver disease (fibrosis and cirrhosis) caused by protein aggregation. As of 2025, the program is in preclinical development.
- Other names
- Congruence A1AT corrector
02
Targets
SERPINA1 Z (Alpha-1-antitrypsin Z variant protein)
Beyond the preview
Go deeper on CO-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CO-2.